174 related articles for article (PubMed ID: 32356244)
1. Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy.
Guan J; Cai N; Liu LM; Zhao N; Liu NN
Diabetes Ther; 2020 Jun; 11(6):1397-1406. PubMed ID: 32356244
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy.
Hu L; Chen Q; Du Z; Wang W; Zhao G
Int Ophthalmol; 2021 May; 41(5):1635-1642. PubMed ID: 33538931
[TBL] [Abstract][Full Text] [Related]
4. Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients.
Li S; Tang J; Han X; Wang Z; Zhang L; Zhao M; Qu J
Ophthalmol Ther; 2022 Oct; 11(5):1833-1845. PubMed ID: 35904708
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of internal limiting membrane peeling for diabetic macular edema after preoperative anti-vascular endothelial growth factor injection.
Guo J; Bi X; Chen SN; Chen S; He GH; Wu B; Zhang W; Wang J
Int J Ophthalmol; 2020; 13(11):1758-1764. PubMed ID: 33215007
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.
Cui J; Chen H; Lu H; Dong F; Wei D; Jiao Y; Charles S; Gu W; Wang L
J Ophthalmol; 2018; 2018():4927259. PubMed ID: 30046459
[TBL] [Abstract][Full Text] [Related]
7. [Pars plana vitrectomy and combination therapy pars plana vitrectomy, intravitreal triamcinolon acetonid and macular lasercoagulation - one year results].
Stefaničková J; Strmeň P; Vavrová K; Mrózová L; Krásnik V
Cesk Slov Oftalmol; 2012 Nov; 68(5):180-8. PubMed ID: 23461369
[TBL] [Abstract][Full Text] [Related]
8. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling.
Yamada Y; Suzuma K; Kumagami T; Fujikawa A; Kitaoka T
Ophthalmologica; 2013; 229(3):142-6. PubMed ID: 23257613
[TBL] [Abstract][Full Text] [Related]
9. Study on the effects of ranibizumab as a pretreatment for vitrectomy in proliferative diabetic retinopathy: a retrospective cohort study.
Zhou HW; Chen K
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5939-5945. PubMed ID: 36066170
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a Meta-analysis.
Hu XY; Liu H; Wang LN; Ding YZ; Luan J
Int J Ophthalmol; 2018; 11(11):1848-1855. PubMed ID: 30450318
[TBL] [Abstract][Full Text] [Related]
11. LONG-TERM OUTCOMES OF 23-GAUGE PARS PLANA VITRECTOMY WITH INTERNAL LIMITING MEMBRANE PEELING AND GAS TAMPONADE FOR MYOPIC TRACTION MACULOPATHY: A Prospective Study.
Figueroa MS; Ruiz-Moreno JM; Gonzalez del Valle F; Govetto A; de la Vega C; Plascencia RN; Contreras I; Medina JL
Retina; 2015 Sep; 35(9):1836-43. PubMed ID: 25946689
[TBL] [Abstract][Full Text] [Related]
12. Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane.
Radetzky S; Walter P; Fauser S; Koizumi K; Kirchhof B; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2004 Apr; 242(4):273-8. PubMed ID: 15042375
[TBL] [Abstract][Full Text] [Related]
13. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema.
Dehghan MH; Salehipour M; Naghib J; Babaeian M; Karimi S; Yaseri M
J Ophthalmic Vis Res; 2010 Jul; 5(3):162-7. PubMed ID: 22737351
[TBL] [Abstract][Full Text] [Related]
14. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Yannuzzi NA; Smiddy WE
Ophthalmology; 2018 Sep; 125(9):1393-1400. PubMed ID: 29606379
[TBL] [Abstract][Full Text] [Related]
15. ILM peeling in nontractional diabetic macular edema: review and metanalysis.
Rinaldi M; dell'Omo R; Morescalchi F; Semeraro F; Gambicorti E; Cacciatore F; Chiosi F; Costagliola C
Int Ophthalmol; 2018 Dec; 38(6):2709-2714. PubMed ID: 29090356
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes.
Koyanagi Y; Yoshida S; Kobayashi Y; Kubo Y; Yamaguchi M; Nakama T; Nakao S; Ikeda Y; Ohshima Y; Ishibashi T; Sonoda KH
Ophthalmologica; 2016; 236(2):67-73. PubMed ID: 27362944
[TBL] [Abstract][Full Text] [Related]
17. THE EFFECT OF INTERNAL LIMITING MEMBRANE PEELING ON IDIOPATHIC EPIRETINAL MEMBRANE SURGERY, WITH A REVIEW OF THE LITERATURE.
Schechet SA; DeVience E; Thompson JT
Retina; 2017 May; 37(5):873-880. PubMed ID: 27617536
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial.
Li S; Guo L; Zhou P; Tang J; Wang Z; Zhang L; Zhao M; Qu J
Eye Vis (Lond); 2022 Dec; 9(1):44. PubMed ID: 36451252
[TBL] [Abstract][Full Text] [Related]
19. EFFECT OF INTERNAL LIMITING MEMBRANE PEELING ON LONG-TERM VISUAL OUTCOMES FOR DIABETIC MACULAR EDEMA.
Kumagai K; Hangai M; Ogino N; Larson E
Retina; 2015 Jul; 35(7):1422-8. PubMed ID: 26102439
[TBL] [Abstract][Full Text] [Related]
20. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review.
Liu WS; Li YJ
Int J Ophthalmol; 2019; 12(9):1479-1486. PubMed ID: 31544046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
